<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149302">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01156675</url>
  </required_header>
  <id_info>
    <org_study_id>GPR003</org_study_id>
    <nct_id>NCT01156675</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety and Effectiveness of the FLEXUS(TM) Interspinous Spacer</brief_title>
  <official_title>A Prospective Randomized Clinical Investigation of the FLEXUS(TM) Interspinous Spacer: A Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Globus Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Globus Medical Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to evaluate the safety and effectiveness of the FLEXUS™
      Interspinous Spacer as compared to the XSTOP® Spacer for the treatment of patients who are
      suffering from lumbar spinal stenosis at one or two contiguous levels.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in pain/disability using the Zurich Claudication Questionnaire (ZCQ) score at 24 months compared with the score at baseline</measure>
    <time_frame>Baseline, 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disability score using the Oswestry Disability Index (ODI) score at 24 months compared with the score at baseline</measure>
    <time_frame>Baseline, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores for back and leg pain using the Visual Analog Scale (VAS) scores at 24 months compared with the scores at baseline</measure>
    <time_frame>Baseline, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments using the SF-36 questionnaire at baseline and 24 months</measure>
    <time_frame>Baseline, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic assessments using x-rays taken at baseline and 24 months</measure>
    <time_frame>Baseline, 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Lumbar Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>FLEXUS™ Interspinous Spacer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>XSTOP® Interspinous Spacer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FLEXUS(TM) Interspinous Spacer</intervention_name>
    <description>Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer</description>
    <arm_group_label>FLEXUS™ Interspinous Spacer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XSTOP® Interspinous Spacer</intervention_name>
    <description>Treatment of lumbar spinal stenosis with the XSTOP® Spacer</description>
    <arm_group_label>XSTOP® Interspinous Spacer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lumbar spinal stenosis as defined by leg, buttock or groin pain, with or without back
             pain, that relieves during flexion, with radiographic confirmation of spinal stenosis
             by CT or MRI scans at one or two contiguous levels between L1 and S1. If back pain is
             also present, it must be partially relieved during flexion

          -  Narrowing of the spinal canal, nerve root canal or intervertebral foramen at one or
             two levels

          -  Able to sit for 50 minutes without pain

          -  Able to walk 50 feet or more

          -  Age 50 years or over

          -  Has completed at least 6 months of conservative treatment

          -  Has a Zurich Claudication Questionnaire (ZCQ) score of ≥ 1.5 for Physical Function
             (PF) and ≥ 1.5 for Symptom Severity (SS)

          -  Other as specified in the approved protocol

        Exclusion Criteria:

          -  Cannot sit for 50 minutes without pain

          -  Cannot walk for more than 50 feet

          -  Unremitting pain in any spinal position

          -  Axial back pain only without leg, buttock, or groin pain

          -  Fixed motor deficit

          -  Cauda equine syndrome, defined as neural compression causing neurogenic bowel (rectal
             incontinence) or bladder (bladder retension or incontinence) dysfunction

          -  Severe symptomatic lumbar spinal stenosis at more than two levels

          -  Significant instability of the lumbar spine

          -  Has had any surgery of the lumbar spine

          -  Morbid obesity defined as a body mass index &gt;40 or a weight more than 100 lbs over
             ideal body weight

          -  Active systemic disease such as AIDS, HIV, Hepatitis, etc.

          -  Active systemic or local infection

          -  Angina, active rheumatoid arthritis, advanced diabetes or any other systemic disease
             that would affect the subject's welfare or outcome of the study

          -  Osteoporosis, defined as DEXA bone density measured T-score &lt; -2.5

          -  Spinal metastasis to the vertebrae

          -  Known allergy to device materials titanium, tantalum, or polyetheretherketone (PEEK)
             polymer

          -  Other as specified in approved protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Skyridge Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>July 1, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Back pain</keyword>
  <keyword>Pain</keyword>
  <keyword>Spinal Diseases</keyword>
  <keyword>Spinal Stenosis</keyword>
  <keyword>Lumbar Vertebrae</keyword>
  <keyword>Spinal Canal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spinal Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
